International Stem Cell (OTCMKTS:ISCO) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of International Stem Cell (OTCMKTS:ISCO) from a hold rating to a sell rating in a research report report published on Tuesday, reports.

According to Zacks, “International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO’s objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be differentiated into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. “

Shares of OTCMKTS ISCO opened at $0.94 on Tuesday. The company has a market capitalization of $7.08 million, a price-to-earnings ratio of -2.85 and a beta of 0.51. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.46 and a current ratio of 0.79. International Stem Cell has a 1-year low of $0.68 and a 1-year high of $1.90. The business’s 50 day moving average price is $0.90.

International Stem Cell (OTCMKTS:ISCO) last announced its earnings results on Friday, May 17th. The biotechnology company reported ($0.12) earnings per share for the quarter. The firm had revenue of $2.22 million for the quarter. International Stem Cell had a negative return on equity of 52.75% and a negative net margin of 12.51%. On average, research analysts predict that International Stem Cell will post -0.39 earnings per share for the current fiscal year.

About International Stem Cell

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes.

See Also: Quiet Period Expirations Explained

Get a free copy of the Zacks research report on International Stem Cell (ISCO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with's FREE daily email newsletter.